BRAF mutations might be related to the particularly high frequency of treatment failure among colon NEC, where up to 65% have immediate progression on first-line treatment with cis/carboplatin and etoposide [6, 29]. The gene discussed is BRAF; the disease is neuroendocrine carcinoma.